The BATTLE trial: A bold step toward improving the efficiency of biomarker-based drug development

Cancer Discovery

Volumn 1, Issue 1, 2011, Pages 17-20

  Rubin, Eric H ^a   Anderson, Keaven M ^a   Gause, Christine K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; AGATOLIMOD; BCR ABL PROTEIN; BEVACIZUMAB; BEXAROTENE; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FIGITUMUMAB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEMETREXED; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; SELUMETINIB; SOMATOMEDIN C RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VADIMEZAN; VANDETANIB; VASCULOTROPIN; VEMURAFENIB;

ADJUVANT THERAPY; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DNA HYBRIDIZATION; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METASTASIS; ONCOGENE RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT OUTCOME;

FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 80051533002     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8274.CD-11-0036     Document Type: Article

References (14)

1. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discovery 2011;1:OF42-OF51.
2. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 1989;81:1616-25.
3. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
4. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009;4:e7273.
5. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 2010;16: 4654-65.
6. Baggerly K, Coombes K. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat 2009;3:1309-34.
7. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
8. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
9. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008;5:181-93.
10. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008;14:4368-71.
11. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
12. Korn EL, Freidlin B. Outcome-adaptive randomization: is it useful? J Clin Oncol 2011;29:771-6.
13. Baker SG, Sargent DJ. Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst 2010;102:1756-9.
14. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.